What if one of the most widely
used therapies in cancer treatment
could be made more effective?
Our Mission
Our mission is simple: to amplify the effectiveness of the backbone of the most widely utilized cancer therapies, so treatments relied upon by millions of patients work better and can work effectively again when resistance appears.
CV6-168
At CV6 Therapeutics, we are developing CV6-168, a first-in-class drug designed to amplify the activity of 5-fluorouracil (5-FU).
CV6-168 promotes uracil incorporation into DNA, increasing cancer cell DNA damage while stimulating innate immune responses. This approach is designed to enhance the performance of 5-FU, a backbone therapy used in millions of patients worldwide.
The program is currently advancing through clinical development.
If CV6-168 performs as expected, it could fundamentally change how we use 5-FU in cancer treatment.
Latest News
View all
Test Press Release
Lorem ipsum dolor sit amet consectetur. Id mi eu non elementum lectus. Lorem turpis morbi varius amet. Convallis sed pretium vitae rhoncus elit. Sed at ut quisque massa faucibus nisl eget...
CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting
Lorem ipsum dolor sit amet consectetur. Id mi eu non elementum lectus. Lorem turpis morbi varius amet. Convallis sed pretium vitae rhoncus elit. Sed at ut quisque massa faucibus nisl eget...